Abstract:The recognition of nucleic acids by the innate immune system during viral infection results in the production of type I interferons and the activation of antiviral immune responses. The RNA helicases RIG-I and MDA-5 recognize distinct types of cytosolic RNA species and signal through the mitochondrial protein MAVS to stimulate the phosphorylation and activation of the transcription factors IRF3 and IRF7, thereby inducing type I interferon expression. Alternatively, the activation of NF-kappaB leads to proinflammatory cytokine production. The function of MAVS is dependent on both its C-terminal transmembrane (TM) domain and N-terminal caspase recruitment domain (CARD). The TM domain mediates MAVS dimerization in response to viral RNA, allowing the CARD to bind to and activate the downstream effector TRAF3. Notably, dimerization of the MAVS CARD alone is sufficient to activate IRF3, IRF7, and NF-kappaB. However, TRAF3-deficient cells display only a partial reduction in interferon production in response to RNA virus infection and are not defective in NF-kappaB activation. Here we find that the related ubiquitin ligase TRAF5 is a downstream target of MAVS that mediates both IRF3 and NF-kappaB activation. The TM domain of MAVS allows it to dimerize and thereby associate with TRAF5 and induce its ubiquitination in a CARD-dependent manner. Also, NEMO is recruited to the dimerized MAVS CARD domain in a TRAF3 and TRAF5-dependent manner. Thus, our findings reveal a possible function for TRAF5 in mediating the activation of IRF3 and NF-kappaB downstream of MAVS through the recruitment of NEMO. TRAF5 may be a key molecule in the innate response against viral infection.

The mitochondrial E3 ubiquitin ligase MARCH5 resolves MAVS aggregates during antiviral signaling.

The mitochondrial ubiquitin ligase MARCH5 resolves MAVS aggregates during antiviral signalling

The mitochodnrial E3 ligase MARCH5 resolves RIG-I and MAVS aggregates in innate immunity

MAVS O-GlcNAcylation is Essential for Host Antiviral Immunity Against Lethal RNA Viruses.

Mitochondria ubiquitin ligase, MARCH5 resolves hepatitis B virus X protein aggregates in the liver pathogenesis

MAVS Cys508 palmitoylation promotes its aggregation on the mitochondrial outer membrane and antiviral innate immunity

MicroRNA-33/33* Inhibit the Activation of MAVS Through AMPK in Antiviral Innate Immunity

TRAF5 is a downstream target of MAVS in antiviral innate immune signaling

MAVS: A Two-Sided CARD Mediating Antiviral Innate Immune Signaling and Regulating Immune Homeostasis

Avian Metapneumovirus Subgroup C Induces Mitochondrial Antiviral Signaling Protein Degradation through the Ubiquitin-Proteasome Pathway

MAVS Promotes Inflammasome Activation by Targeting ASC for K63-Linked Ubiquitination via the E3 Ligase TRAF3.

MAVS Maintains Mitochondrial Homeostasis Via Autophagy

Autophagy regulates MAVS signaling activation in a phosphorylation-dependent manner in microglia

Palmitoylation acts as a checkpoint for MAVS aggregation to promote antiviral innate immune responses

Genome-Wide CRISPR/Cas9 Screening Identifies That Mitochondrial Solute Carrier SLC25A23 Attenuates Type I IFN Antiviral Immunity Via Interfering with MAVS Aggregation.

COX5B Regulates MAVS-mediated Antiviral Signaling Through Interaction with ATG5 and Repressing ROS Production

PGAM5-MAVS Interaction Regulates TBK1/ IRF3 Dependent Antiviral Responses

FAF1 Regulates Antiviral Immunity by Inhibiting MAVS but is Antagonized by Phosphorylation Upon Viral Infection.

Arginine monomethylation by PRMT7 controls MAVS-mediated antiviral innate immunity

Virus Infection Triggers MAVS Polymers of Distinct Molecular Weight

MAVS deSUMOylation by SENP1 inhibits its aggregation and antagonizes IRF3 activation